Tada, what an interesting observation.

Don has talked for years about making money from the blood bank. To my knowledge no revenue has ever been generated from this data source.

Perhaps retention of blood banks is a "best practice standard" among the hundreds and hundreds of biotech labs around the globe so perhaps there is no demand? However, I do recall Don saying the RVX and Zenith blood banks are proprietary. Hence, this is one of the reasons/ or benefits to an acquisitor to make a purchase offer.

Any thoughts?

As a side thought it is diffcult to see the share price at $1.80 given that RVX and apabetalone is more advanced than it ever has been scientifically and it is debt free. I would have thought that there would be far more action on the speculative side. However, I'm not a trader and I don't understand that side of it. I think there needs to be either a rumour or expectation of a very significant event about to happen to drive trading levels. Perhaps that will be the completion of BoM?

GLTA

Toinv